Summary Summary The European Medicines
The European Medicines Agency (EMEA) is the regulatory body Agency (EMEA) is the regulatory body that provides the institutions of the that provides the institutions of the European Community with the best European Community with the best possible scientific advice on the quality, possible scientific advice on the quality, safety and efficacy of medicinal products. safety and efficacy of medicinal products. Drugs approved by the EMEA are Drugs approved by the EMEA are automatically marketable in all the automatically marketable in all the European member states. Since the European member states. Since the beginning of the EMEA's activities a beginning of the EMEA's activities a number of drugs acting on the central number of drugs acting on the central nervous system obtained marketing nervous system obtained marketing authorisation.This editorial highlights authorisation.This editorial highlights some aspects of the EMEA rules that may some aspects of the EMEA rules that may negatively affectthe evaluation of negatively affect the evaluation of medicines for psychiatric disorders. medicines for psychiatric disorders.
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The recent revision of the European pharThe recent revision of the European pharmaceutical legislation has given the maceutical legislation has given the European Medicines Agency (EMEA) new European Medicines Agency (EMEA) new responsibilities. After more than 10 years responsibilities. After more than 10 years of existence the EMEA has proved useful of existence the EMEA has proved useful in ensuring member states shift towards in ensuring member states shift towards harmonisation of pharmaceutical harmonisation of pharmaceutical proceprocedures and simplification of the process dures and simplification of the process by by which a central authorisation becomes which a central authorisation becomes valid in all the states (Garattini & Bertele', valid in all the states (Garattini & Bertele', 2001 ). Any opinion expressed by the 2001). Any opinion expressed by the EMEA on old or new products, relating to EMEA on old or new products, relating to changes in therapeutic indications, apchanges in therapeutic indications, approval, suspension or withdrawal of a proproval, suspension or withdrawal of a product, has to be accepted by all members of duct, has to be accepted by all members of the European Union. The system includes a the European Union. The system includes a centralised procedure, through the EMEA, centralised procedure, through the EMEA, and a decentralised procedure, whereby a and a decentralised procedure, whereby a new drug approved by one member state is new drug approved by one member state is accepted by the others after the procedure accepted by the others after the procedure of mutual recognition. ) has extended the list of drugs that must go through the cenlist of drugs that must go through the centralised procedure (Garattini tralised procedure (Garattini et al et al, 2003) . , 2003). Since its establishment the EMEA has Since its establishment the EMEA has issued recommendations, notes for guidissued recommendations, notes for guidance, conceptual papers and other official ance, conceptual papers and other official documents intended to guide the design documents intended to guide the design and reporting of randomised controlled and reporting of randomised controlled trials conducted for regulatory purposes. trials conducted for regulatory purposes. These official documents report the EMEA These official documents report the EMEA rules and criteria for approval of new rules and criteria for approval of new drugs. So far, nine products acting on the drugs. So far, nine products acting on the central nervous system have been approved central nervous system have been approved in line with these criteria, and in future in line with these criteria, and in future years it is expected that the increasing reyears it is expected that the increasing responsibilities of the EMEA will progressponsibilities of the EMEA will progressively increase the number of products for sively increase the number of products for psychiatric disorders submitted for appsychiatric disorders submitted for approval (Garattini & Bertele', 2003) . In this proval (Garattini & Bertele', 2003) . In this still-evolving European scenario, at least still-evolving European scenario, at least three technical aspects of the EMEA rules three technical aspects of the EMEA rules may negatively affect the evaluation of may negatively affect the evaluation of medicines for psychiatric disorders. medicines for psychiatric disorders.
PROCEDURES FOR DRUG PROCEDURES FOR DRUG APPROVAL APPROVAL
The centralised procedure is not compulThe centralised procedure is not compulsory for psychotropic drugs. In addition to sory for psychotropic drugs. In addition to the fact that the dual system of the fact that the dual system of approval -centralised and decentralisedapproval -centralised and decentralisedcreates competition between the EMEA creates competition between the EMEA and the national drug agencies, with finanand the national drug agencies, with financial implications, it generates heterogeneity cial implications, it generates heterogeneity between countries in terms of approved inbetween countries in terms of approved indications (labels). Olanzapine, for example, dications (labels). Olanzapine, for example, has been positively assessed by the EMEA has been positively assessed by the EMEA through the centralised procedure and rethrough the centralised procedure and released for marketing with the same label leased for marketing with the same label in all EU member states. However, a decenin all EU member states. However, a decentralised route has been followed in the case tralised route has been followed in the case of quetiapine, marketed after 1995, and apof quetiapine, marketed after 1995, and approved for the treatment of schizophrenia proved for the treatment of schizophrenia in the UK and for the treatment of 'acute in the UK and for the treatment of 'acute and chronic psychoses, including schizoand chronic psychoses, including schizophrenia', in Italy (Barbui phrenia', in Italy (Barbui et al et al, 2003) . , 2003). Labels have a key role in regulating the Labels have a key role in regulating the everyday prescribing and consumption of everyday prescribing and consumption of drugs: in Italy quetiapine is the only atypidrugs: in Italy quetiapine is the only atypical antipsychotic that can be prescribed in cal antipsychotic that can be prescribed in patients without a diagnosis of schizopatients without a diagnosis of schizophrenia or bipolar disorder. Off-label prephrenia or bipolar disorder. Off-label prescribing is not forbidden, but implies that scribing is not forbidden, but implies that doctors take full responsibility for the predoctors take full responsibility for the prescription and that patients give informed scription and that patients give informed consent and pay the full price of the drug, consent and pay the full price of the drug, as reimbursement is usually restricted to as reimbursement is usually restricted to disorders stated in the label. Theoretically, disorders stated in the label. Theoretically, approved labels should correspond to trial approved labels should correspond to trial inclusion criteria, and it seems rather inclusion criteria, and it seems rather contradictory that European regulatory contradictory that European regulatory authorities, while strongly supporting the authorities, while strongly supporting the adoption of stringent inclusion criteria in adoption of stringent inclusion criteria in clinical trials, with rigorous and restrictive clinical trials, with rigorous and restrictive reference to diagnostic rules, permit drugs reference to diagnostic rules, permit drugs to be licensed with generic and unspecific to be licensed with generic and unspecific labels for use in clinical practice. Probably, labels for use in clinical practice. Probably, only the abolition of the decentralised proonly the abolition of the decentralised procedure will make the licensed indications of cedure will make the licensed indications of new drugs more consistent. new drugs more consistent.
CONTROLLED TRIALS CONTROLLED TRIALS
At the EMEA new drugs can still be evaluAt the EMEA new drugs can still be evaluated with no comparison with active alterated with no comparison with active alternative treatments. This means that new native treatments. This means that new drugs can be proved effective and safe on drugs can be proved effective and safe on their own, even though they might in fact their own, even though they might in fact be potentially less effective or less safe than be potentially less effective or less safe than other drugs currently in use. Although in other drugs currently in use. Although in situations where no (or only a few) active situations where no (or only a few) active treatments are available this issue may not treatments are available this issue may not be relevant, in the field of psychotropic be relevant, in the field of psychotropic drugs, where many effective agents are availdrugs, where many effective agents are available, this issue is crucial. Despite this, the deable, this issue is crucial. Despite this, the demonstration of a difference against placebo, monstration of a difference against placebo, and not against an active comparator, makes and not against an active comparator, makes a new psychotropic drug eligible for registraa new psychotropic drug eligible for registration in Europe. If comparisons are made, the tion in Europe. If comparisons are made, the industry usually relies on demonstrating industry usually relies on demonstrating therapeutic 'equivalence' or 'non-inferiority', therapeutic 'equivalence' or 'non-inferiority', because this is in agreement with current because this is in agreement with current EMEA requirements. This results in a high EMEA requirements. This results in a high degree of uncertainty about the therapeutic degree of uncertainty about the therapeutic role of new drugs. Even the recent revision role of new drugs. Even the recent revision of the European pharmaceutical legislation of the European pharmaceutical legislation does not include the requirement that, when does not include the requirement that, when feasible, clinical studies should be conducted feasible, clinical studies should be conducted in comparison with reference drugs (in acin comparison with reference drugs (in accordance with the Declaration of Helsinki) cordance with the Declaration of Helsinki) to establish the relative benefit of a new to establish the relative benefit of a new drug. In terms of public health needs, the drug. In terms of public health needs, the concept of added value should be introduced concept of added value should be introduced into the legislation. This concept has two into the legislation. This concept has two
positive consequences. First, it allows deterpositive consequences. First, it allows determination of whether a drug is active. If commination of whether a drug is active. If comparative trials show that a new drug is more parative trials show that a new drug is more effective than a standard one, it means that effective than a standard one, it means that the new drug is active. Conversely, if a new the new drug is active. Conversely, if a new drug is not more effective than a standard drug is not more effective than a standard one, it means that the new drug is inactive one, it means that the new drug is inactive or similarly active compared with the referor similarly active compared with the reference. In the latter scenario there is no added ence. In the latter scenario there is no added value. Second, the concept of added value value. Second, the concept of added value would advance innovation in the developwould advance innovation in the development of drugs, because a higher threshold ment of drugs, because a higher threshold for the entry of new drugs would force invesfor the entry of new drugs would force investigators towards the development of innovatigators towards the development of innovative rather than 'me too' drugs. The current tive rather than 'me too' drugs. The current legislation, allowing investigators to demonlegislation, allowing investigators to demonstrate a difference against placebo, has enstrate a difference against placebo, has encouraged the marketing of drugs with little couraged the marketing of drugs with little degree of innovation. Investigators should degree of innovation. Investigators should be induced to design and conduct clinical be induced to design and conduct clinical trials aimed at discovering better activity, trials aimed at discovering better activity, beneficial effects on different populations, beneficial effects on different populations, and less or different toxicity. and less or different toxicity.
Methodological considerations also Methodological considerations also should be taken into account. Recent data should be taken into account. Recent data have shown that placebo-controlled trials, have shown that placebo-controlled trials, in comparison with active-controlled trials, in comparison with active-controlled trials, tend to overemphasise the occurrence of tend to overemphasise the occurrence of hard outcomes, such as the rate of particihard outcomes, such as the rate of participants withdrawing from treatment ('droppants withdrawing from treatment ('dropouts'). In antipsychotic drug trials, for outs'). In antipsychotic drug trials, for example, a systematic review showed that example, a systematic review showed that the proportion of participants disconthe proportion of participants discontinuing antipsychotics was substantially tinuing antipsychotics was substantially higher in placebo-controlled trials than in higher in placebo-controlled trials than in active-control clinical trials (Kemmler active-control clinical trials (Kemmler et et al al, 2005) . In the field of psychotropic drugs, , 2005). In the field of psychotropic drugs, where withdrawal rates approaching or where withdrawal rates approaching or exceeding 50% are not uncommon, this exceeding 50% are not uncommon, this may produce a problem of biased estimamay produce a problem of biased estimation of treatment effect, leading to tion of treatment effect, leading to erroneous conclusions and poor generalisaerroneous conclusions and poor generalisability. Future revisions of the European bility. Future revisions of the European pharmaceutical legislation should incorpopharmaceutical legislation should incorporate the requirement of active-control clinirate the requirement of active-control clinical trials in the evaluation of psychotropic cal trials in the evaluation of psychotropic drugs, at least in addition to placebodrugs, at least in addition to placebocontrolled trials. Active-control clinical controlled trials. Active-control clinical trials should be designed and powered to trials should be designed and powered to generate evidence of superiority (added generate evidence of superiority (added value), providing physicians with clear value), providing physicians with clear indications on the therapeutic role of new indications on the therapeutic role of new medicines, with respect to older medicines medicines, with respect to older medicines already on the market. already on the market.
OUTCOMES OUTCOMES
A third aspect, particularly relevant to the A third aspect, particularly relevant to the evaluation of psychotropic drugs, is the evaluation of psychotropic drugs, is the choice of the outcome of interest. Whereas choice of the outcome of interest. Whereas in other fields of medicine the definition in other fields of medicine the definition of outcome measures may be a relatively of outcome measures may be a relatively straightforward task, in psychiatric disorstraightforward task, in psychiatric disorders treatment efficacy may often be an eluders treatment efficacy may often be an elusive concept, typically quantified by means sive concept, typically quantified by means of rating scales. The EMEA guidance on of rating scales. The EMEA guidance on this issue recognises that although improvethis issue recognises that although improvement in symptoms should be documented ment in symptoms should be documented as a difference between baseline and postas a difference between baseline and posttreatment score, in order to allow an estitreatment score, in order to allow an estimate of clinical relevance the proportion mate of clinical relevance the proportion of 'responders' or 'remitters' should be of 'responders' or 'remitters' should be presented. Cut-off points should be defined presented. Cut-off points should be defined a priori a priori in the protocol. From a practical in the protocol. From a practical viewpoint this seems reasonable because it viewpoint this seems reasonable because it allows physicians to make judgements in allows physicians to make judgements in terms of proportion of patients (and not terms of proportion of patients (and not means and standard deviations), absolute means and standard deviations), absolute and relative risk differences and number and relative risk differences and number needed to treat (Barbui needed to treat . Unfor-, 2001 ). Unfortunately, this approach systematically magtunately, this approach systematically magnifies the effect of new medicines against nifies the effect of new medicines against placebo. A situation was hypothesised of a placebo. A situation was hypothesised of a 1-point difference in mean change in scores 1-point difference in mean change in scores on the Hamilton Rating Scale for Depression on the Hamilton Rating Scale for Depression between drug and placebo, and it was shown between drug and placebo, and it was shown that by defining response as a minimum 12-that by defining response as a minimum 12-point improvement on this scale a response point improvement on this scale a response rate of 50% in the drug condition and rate of 50% in the drug condition and 32% in the placebo condition could be ob-32% in the placebo condition could be obtained (Moncrieff & Kirsch, 2005) . A small tained (Moncrieff & Kirsch, 2005) . A small difference in symptom score can thus be difference in symptom score can thus be translated into a large and clinically relevant translated into a large and clinically relevant difference in proportions. difference in proportions.
The EMEA rules should consider scores The EMEA rules should consider scores from rating scales and their categorisation from rating scales and their categorisation as secondary outcome measures. Randomas secondary outcome measures. Randomised controlled trials conducted for regulaised controlled trials conducted for regulatory purposes should increasingly use, as tory purposes should increasingly use, as primary outcomes, hard and practical meaprimary outcomes, hard and practical measures such as suicide attempts, treatment sures such as suicide attempts, treatment switching, hospitalisation, school failure switching, hospitalisation, school failure or truancy, job loss or even withdrawal or truancy, job loss or even withdrawal from the trial itself (Tansella from the trial itself (Tansella et al et al, 2006) . , 2006). The example provided by the Clinical AntiThe example provided by the Clinical Antipsychotic Trials of Intervention Effectivepsychotic Trials of Intervention Effectiveness is paradigmatic in this regard ness is paradigmatic in this regard (Lieberman (Lieberman et al et al, 2005) . This study, which , 2005). This study, which randomly assigned a total of 1493 patients randomly assigned a total of 1493 patients with schizophrenia to receive olanzapine, with schizophrenia to receive olanzapine, perphenazine, quetiapine or risperidone perphenazine, quetiapine or risperidone for up to 18 months, employed as primary for up to 18 months, employed as primary outcome the discontinuation of treatment outcome the discontinuation of treatment for any cause. This discrete outcome was for any cause. This discrete outcome was selected on the assumption that stopping selected on the assumption that stopping or changing medication is a frequent or changing medication is a frequent occurrence and a major problem in the occurrence and a major problem in the treatment of schizophrenia. The finding treatment of schizophrenia. The finding that 74% of patients discontinued the study that 74% of patients discontinued the study medication within 18 months is a clear conmedication within 18 months is a clear confirmation of the relevance of this outcome firmation of the relevance of this outcome (Lieberman (Lieberman et al et al, 2005) . A similar , 2005). A similar approach has been followed by the Bipolar approach has been followed by the Bipolar Affective Disorder Lithium Anticonvulsant Affective Disorder Lithium Anticonvulsant Evaluation trial, where hospital admission Evaluation trial, where hospital admission was defined as the primary outcome was defined as the primary outcome (Geddes & Goodwin, 2001 ). In these cir- (Geddes & Goodwin, 2001 ). In these circumstances, the idea that hard outcome cumstances, the idea that hard outcome measures are suitable for practical and measures are suitable for practical and pragmatic clinical trials, but not for ranpragmatic clinical trials, but not for randomised controlled trials conducted for domised controlled trials conducted for regulatory purposes, appears difficult to regulatory purposes, appears difficult to reconcile with the principles of evidencereconcile with the principles of evidencebased medicine. based medicine.
CONCLUSION CONCLUSION
In Europe, current policies on medicines for In Europe, current policies on medicines for psychiatric disorders need to be further depsychiatric disorders need to be further developed in order to fully comply with the veloped in order to fully comply with the EMEA mission statement of promoting EMEA mission statement of promoting 'the protection of human health . . . and 'the protection of human health . . . and of con of consumers of medicinal products' sumers of medicinal products' (Council of the European Communities, (Council of the European Communities, 1993). 1993). 
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